Related Experiment Video
Updated: Jun 4, 2025

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
Published on: November 22, 2016
Regulatory preparedness for multicomponent nanomaterials: Current state, gaps and challenges of REACH
Neil Hunt1, Vikram Kestens2, Kirsten Rasmussen3
1YORDAS Group, Lancaster Environment Centre, Lancaster University, Lancaster, UK.
Abstract:
In 2018 the European Commission adopted revisions to the Annexes of Regulation (EC) No 1907/2006 concerning registration, evaluation, authorisation and restriction of chemicals (REACH) to introduce nanomaterial-specific clarifications and provisions. Multicomponent nanomaterial (MCNM) is a non-regulatory term that has been used in recent EU-funded projects to describe nanomaterials with a complex structure and/or composition and which are expected to be increasingly used in products in the near future. This paper examines the regulatory preparedness of REACH, and its revised Annexes, for MCNMs. Several situations have been identified where there is potential confusion and uncertainty around how regulatory definitions used in REACH should be applied to MCNMs. If a MCNM cannot be identified as falling within a specific definition, understanding the regulatory obligations that apply to it is very difficult. Examples of these grey areas include how the term "surface functionalisation or modification" applies when a chemical is physisorbed to the surface of a nanoform, and the identity of the substance that should be registered when the modification takes it outside the definition of a nanoform. We conclude that the regulatory preparedness can be improved by amending the REACH guidance on information requirements for nanoforms and revising the definition of "nanoform" in line with the updated EC Recommendation on the definition of nanomaterial.
Related Concept Videos
Preclinical Development: Overview
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

